These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35477179)

  • 61. Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.
    Iannello A; Vitale N; Coma S; Arruga F; Chadburn A; Di Napoli A; Laudanna C; Allan JN; Furman RR; Pachter JA; Deaglio S; Vaisitti T
    Blood; 2021 Jun; 137(24):3378-3389. PubMed ID: 33786583
    [TBL] [Abstract][Full Text] [Related]  

  • 62. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
    Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
    J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
    Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy.
    Liu J; Xavy S; Mihardja S; Chen S; Sompalli K; Feng D; Choi T; Agoram B; Majeti R; Weissman IL; Volkmer JP
    JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32427583
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages.
    Sakamoto M; Murata Y; Tanaka D; Kakuchi Y; Okamoto T; Hazama D; Saito Y; Kotani T; Ohnishi H; Miyasaka M; Fujisawa M; Matozaki T
    Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34949714
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma.
    Casey M; Segawa K; Law SC; Sabdia MB; Nowlan B; Salik B; Lee C; Winterford C; Pearson S; Madore J; Dougall WC; Gandhi MK; Nakamura K
    Leukemia; 2023 Feb; 37(2):379-387. PubMed ID: 36539557
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
    Wang X; Wang Y; Hu J; Xu H
    Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 71. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
    Lin GHY; Chai V; Lee V; Dodge K; Truong T; Wong M; Johnson LD; Linderoth E; Pang X; Winston J; Petrova PS; Uger RA; Viller NN
    PLoS One; 2017; 12(10):e0187262. PubMed ID: 29084248
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
    Tong B; Wang M
    Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential.
    Ma L; Zhu M; Gai J; Li G; Chang Q; Qiao P; Cao L; Chen W; Zhang S; Wan Y
    J Nanobiotechnology; 2020 Jan; 18(1):12. PubMed ID: 31931812
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal.
    Li C; Liu Y; Li D; Wang Q; Zhou S; Zhang H; Wang Y; He Z; Liu H; Sun J
    Theranostics; 2022; 12(10):4581-4598. PubMed ID: 35832081
    [No Abstract]   [Full Text] [Related]  

  • 75. Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma.
    Gifford G; Stevenson W; Best G
    Leuk Lymphoma; 2020 Dec; 61(13):3165-3176. PubMed ID: 32723130
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.
    Haikala HM; Anttila JM; Marques E; Raatikainen T; Ilander M; Hakanen H; Ala-Hongisto H; Savelius M; Balboa D; Von Eyss B; Eskelinen V; Munne P; Nieminen AI; Otonkoski T; Schüler J; Laajala TD; Aittokallio T; Sihto H; Mattson J; Heikkilä P; Leidenius M; Joensuu H; Mustjoki S; Kovanen P; Eilers M; Leverson JD; Klefström J
    Nat Commun; 2019 Feb; 10(1):620. PubMed ID: 30728358
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
    Boiko S; Proia T; San Martin M; Gregory GP; Wu MM; Aryal N; Hattersley M; Shao W; Saeh JC; Fawell SE; Johnstone RW; Drew L; Cidado J
    Blood; 2021 May; 137(21):2947-2957. PubMed ID: 33259592
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A novel CD47-blocking peptide fused to pro-apoptotic KLA repeat inhibits lung cancer growth in mice.
    Pan L; Hu L; Chen M; Song Y; Chen Z; Gu Y; Li C; Jiang Z
    Cancer Immunol Immunother; 2023 Dec; 72(12):4179-4194. PubMed ID: 37831145
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
    Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
    Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
    [No Abstract]   [Full Text] [Related]  

  • 80. Venetoclax: First Global Approval.
    Deeks ED
    Drugs; 2016 Jun; 76(9):979-87. PubMed ID: 27260335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.